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CASE
A 62-year-old never-smoker African American woman 
presented with flashing lights and floaters in the left eye in 
July 2011. Ophthalmic examination revealed visual acuity 
of 20/20 in her right eye and counting fingers in the left. 
Multiple lobulated, yellowish choroidal masses in the left 
eye with overlying subretinal fluid, and two smaller lesions 
in the right eye were identified (Fig. 1A). The clinical find-
ings were highly suggestive of choroidal metastases. She 
underwent positron emission tomography and body com-
puted tomography scans, which revealed a 2.1 × 4.5 cm left 
lower lobe lung mass, with probable angiolymphatic car-
cinomatosis in mid left lung and diffuse adenopathy from 
neck to pelvis (maximum standardized uptake value 10.6) 
(Figure 2A). Bronchoscopic lung mass biopsy revealed ade-
nocarcinoma consistent with lung primary. Brain magnetic 
resonance imaging result was negative. Clinical tumor test-
ing for EGFR mutation and ALK 2p23 translocation by fluo-
rescence in situ hybridization (FISH) both returned originally 
reported as negative. ALK FISH assay was performed before 
approval by the Food and Drug Administration (FDA) as the 
companion diagnostic assay for crizotinib (Abbot Molecular 
Vysis ALK Break Apart Probe Kit; Abbott Molecular, Abbott 
Park, IL), which demonstrated 22% cells having two fusion 
signals and one red signal but no green signals (2F1R0G), an 
atypical pattern originally classified as negative for a classic 
gene rearrangement.
The patient was begun on standard chemotherapy car-
boplatin area under the curve 6 and pemetrexed 500mg/m2 in 
August 2011. She tolerated treatment poorly and was found 
to have tumor progression including diseases in the eyes after 
the third cycle. Palliative radiation (RT) was then delivered to 
both eyes (30 Gy in 10 fractions) but with no resultant clinical 
response. Interestingly, she subsequently experienced good 
partial response and palliative benefit to second-line erlotinib. 
However, this was followed by systemic progression after 
5 months of erlotinib (Fig. 2B), whereas the choroidal metas-
tases remained stable.
During the course of our ongoing translational 
research study evaluating ALK immunohistochemistry 
(IHC) as a potential diagnostic assay in ALK 2p23 translo-
cated (ALK+) lung cancer, her original tumor was found 
to be ALK IHC (+) (Fig. 3). ALK FISH test was repeated 
by using same assay and again demonstrated an atypical 
rearrangement (34% cells having 2F1R0G signal pat-
tern). The recent FDA-approved ALK FISH assay inter-
pretative criteria classify the atypical 2F1R0G pattern as 
positive for ALK rearrangement (>15% cells). The patient 
was therefore started on crizotinib in April 2012, and had 
significant symptomatic improvement and radiographic 
near-complete response after 4 months, lasting up to the 
present (18 months) (Fig. 2C). Strikingly, her left vision 
improved to 20/40, with ocular ultrasound imaging show-
ing no detectable lesion after 10 months of therapy (Fig. 
1B). She currently remains on crizotinib with excellent 
tolerance.
DISCUSSION
Lung cancer is the second most common malignancy. 
Choroidal metastasis from lung cancer is known to occur, 
although as a rare presentation.,1,2 The response of choroi-
dal metastases to systemic chemotherapy or radiation has 
also been reported.3 Our case report is the first to describe 
a patient who had dramatic simultaneous systemic and ocu-
lar disease response to crizotinib, an ALK-tyrosine kinase 
inhibitor, which targets ALK+ lung cancer.4 The remark-
able tumor response to crizotinib in choroidal metastases as 
reported here suggests excellent drug delivery to choroid. 
The patient’s dramatic response during crizotinib therapy is 
unlikely a late effect of radiation, which was completed 6 
months before.
ALK FISH is the FDA-approved companion diagnos-
tic test for ALK 2p23 translocation. However, atypical FISH 
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patterns such as 2F1R0G in our case must be recognized 
as variant rearrangements qualifying patients for crizotinib. 
We also emphasize that not all atypical ALK rearrangements 
are productive of the endocoded protein; specifically, a 
1F1G0R atypical rearrangement is classified as FISH nega-
tive. We recently evaluated an ultrasensitive automated IHC 
in the diagnosis of ALK+ non-small cell lung cancer, com-
paring it with ALK FISH and demonstrated 100% sensitivity 
and specificity.5 ALK IHC could be a cost-effective screen-
ing test to supplement ALK FISH in lung cancer targeted 
therapy.
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FIGURE 1.  Retinal images and ocu-
lar ultrasonography of patient’s left 
(L) and right (R) eye at diagnosis (1A, 
top) and after 10 months of crizo-
tinib therapy (1B, bottom). 
FIGURE 2.  PET/CT scans indicating 
patient’s left lower lobe mass and 
left hilar adenopathy at diagnosis 
(2A), progression after 5 months of 
erlotinib (2B) and complete response 
after 14 months of crizotinib (2C).
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FIGURE 3. ALK immunohistochem-
istry (IHC) expression analysis on 
patient’s tumor (left: 4X, right: 20X).
